Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 09, 2018 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the fourth quarter and fiscal year ended 31 January 2018 on 11 April 2018.
Summit will host a conference call and webcast the same day to discuss its operational progress at 1:00pm BST / 8:00am EDT. Conference call and webcast information will be included in the full year results press release. A replay of the call will also be available through the Company's website, www.summitplc.com, shortly after its conclusion.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | ||
| Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance | ||
| Tom Salvesen, Corporate Broking | ||
| MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
| Karen Sharma | [email protected] | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | [email protected] | |
| Philippa Gardner / Rosie Phillips |
-END-
